Gold J, Sarangapany J, Kelly M, Bridle S; International Conference on AIDS (15th : 2004 : Bangkok, Thailand).

Int Conf AIDS. 2004 Jul 11-16; 15: abstract no. B12689.

Albion Street Centre, Sydney, Australia

Background: Clinical trials have demonstrated atazanavir (AZV) to be potent, safe and well tolerated in both naive and treatment experienced patients. However, little is known about how this drug performs in a clinic setting. This audit was performed to correlate our experience with published reports. Methods: Patients commencing AZV at an outpatient clinic in Australia from July 2003 to December 2003 were identified on the clinic pharmacy's database. Data were retrospectively collected from patients' medical records. Results: 28 patients received AZV during the period. Of these 13 substituted AZV for other antiretroviral agent. The reasons for commencing AZV were virological failure in 6 (21%) of cases and toxicity to previous regimen in 12 (43%) restarting antiretroviral treatment following treatment interruption in 8 (29%) and simplify dosing regimen to once daily in 2 (7%). 5 (17%) discontinued AZV during the observation period.17 patients commenced AZV in combination therapy with a detectable VL. The mean baseline VL was log 4.3 +/- 1.1 copies/ml and the mean period of observation was 5 +/- 3.3 months. During this period 12 (71%) had >1.0 log decrease in VL with 11 (65%) achieving viral suppression to<50 copies/mL. 11 patients commenced AZV with undetectable VL. One virological failure was recorded in this group. This PI-experienced patient did not receive ritonavir boosting. Bilirubin increased by 19.9 mmol/L (p<0.001). Significant decreases in serum cholesterol [1.4 mmol/L, p=0.03] were observed in 6/28 patients who substituted ritonavir-boosted AZV for ritonavir-boosted lopinavir. Mild gastrointestinal disturbance occurred in 50% of patients. Jaundice was reported in only two subjects. Conclusions: This audit found AZV to be safe, well tolerated and have good potency in treatment-experienced patients. However considering there was one failure in the undetectable group, caution should be exercised in switching to AZV in heavily pretreated patients.

Publication Types:

• Meeting Abstracts

Keywords:

• Anti-HIV Agents
• Anti-Retroviral Agents
• Australia
• HIV Protease Inhibitors
• Humans
• Oligopeptides
• Phenothiazines
• Pyridines
• Pyrimidinones
• Reverse Transcriptase Inhibitors
• Ritonavir
• SAS
• atazanavir
• lopinavir

Other ID:

• GWAIDS0032784

UI: 102276998

From Meeting Abstracts